EP Patent

EP3939589A1 — High drug load tablet comprising voxelotor

Assigned to Sandoz AG · Expires 2022-01-19 · 4y expired

What this patent protects

A tablet comprising at least 60% w/w of voxelotor and at least 10% w/w of low-substituted hydroxypropyl cellulose. Process for the preparation of a tablet comprising the process steps of blending voxelotor with low-substituted hydroxypropyl cellulose and, optionally, further exci…

USPTO Abstract

A tablet comprising at least 60% w/w of voxelotor and at least 10% w/w of low-substituted hydroxypropyl cellulose. Process for the preparation of a tablet comprising the process steps of blending voxelotor with low-substituted hydroxypropyl cellulose and, optionally, further excipients and compressing the resulting blend into a tablet. The tablet according for use in the treatment of haematological disorders such as sickle cell disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP3939589A1
Jurisdiction
EP
Classification
—
Expires
2022-01-19
Drug substance claim
No
Drug product claim
No
Assignee
Sandoz AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.